Steigerwald, Gordon & Koch Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Steigerwald, Gordon & Koch Inc.
- $954 Million
- Q4 2025
A detailed history of Steigerwald, Gordon & Koch Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Steigerwald, Gordon & Koch Inc. holds 6 shares of ALNY stock, worth $2,694. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6Holding current value
$2,694% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
923Shares Held
117MCall Options Held
1.25MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA16.4MShares$7.38 Billion1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$6.09 Billion0.09% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.29 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.22MShares$3.24 Billion0.65% of portfolio
-
Jpmorgan Chase & CO New York, NY4.54MShares$2.04 Billion0.14% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $55.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...